Navigation Links
Cardiac Science Announces Third Quarter Results
Date:11/9/2009

r a temporary ship hold, the Company's manufacturing and quality teams performed well, filling the vast majority of open orders that had accumulated during the ship hold. Cardiac monitoring revenue decreased 15% compared to the prior year period, driven by slowed demand in the hospital and physician office markets.

The Company recorded a charge of $18.5 million for estimated costs relating to an initiative to improve the reliability of approximately 300,000 AEDs in the field. The Company has determined that, in very rare instances, AEDs may fail to deliver therapy due to a suspect component. The Company has improved its manufacturing process to enhance component reliability in forward production and has elected to undertake an initiative to further strengthen the reliability of field units. The initiative is expected to cost $18.5 million, but the Company is still in discussion with the FDA and other stakeholders to determine the final scope and details. Actual costs may be more or less than the amount of the estimated charge, based on a number of factors.

In addition, the Company's third quarter results reflect a charge to earnings of $44.0 million to increase its valuation allowance against deferred income tax assets. In light of recent losses, including the $18.5 million charge relating to the anticipated field initiative, the Company has made an assessment that the realization of the benefit of its deferred tax assets, primarily comprised of income tax loss and tax credit carry-forwards, is not "more likely than not" in accordance with applicable GAAP guidelines and has therefore increased its valuation allowance against those assets. This is a non-cash charge that has no impact on the Company's liquidity and the tax loss and credit carry-forwards remain available to offset future cash income taxes when the Company regains profitability.

"Gaining clarity on the financial impact of the component issue will allow all of our stake
'/>"/>

SOURCE Cardiac Science Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related medicine technology :

1. Personalized Medicine - The Genomic Revolution in Cardiac Care
2. FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function
3. Signalife Completes Testing of Modules for Holter and Intra-Cardiac Monitor
4. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
5. Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery
6. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
7. Do-It-Yourself Cardiac Bypass Surgery: All You Need is Walking Shoes
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
10. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
11. Study Finds PCI Safe, Effective Despite Off-Site Cardiac Surgery

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., MADISON,N.J.,Nov.24/PRNewswire-FirstCall/--...sleadingproviderofdiagnostictesting,informationand...tAnnualPiperJaffrayHealthcareConferenceinNewYorkCi...2,2009at9:30a.m.EasternTime. ,, Duringtheconfer...uegrowthtoapproximate3%,operatingincometoexceed18%...
(Date:11/24/2009)..., WOODCLIFFLAKE,N.J.andNEWYORK,Nov.24/PRNewsw...U.S.FoodandDrugAdministration(FDA)hasacceptedforre...Aricept®(donepezilHClextendedrelease)tabletsf...(AD).Thisnewhigherdoseformulationcontains23mgofdon...adeliverysystemthatallowsforgradualreleaseofthedru...
(Date:11/24/2009)..., SANDIEGO,Nov.24/PRNewswire/--Accumetrics,In...ow®System,thefirstrapidandeasy-to-usediagnost...leantiplateletagents(e.g.Plavix®andaspirin),a...ccumetrics,andGregoryJ.Tibbitts,ChiefFinancialOffi...watthe21stAnnualPiperJaffrayHealthCareConferencebe...
Breaking Medicine Technology:Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 3Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference 2A 50 25 Increase in Medical Bankruptcies A Worry for Adults Assisting Aging Parents 49473 1A 50 25 Increase in Medical Bankruptcies A Worry for Adults Assisting Aging Parents 49473 2Generation of a severe memory deficit mutant mouse by exclusively eliminating the kinase activity of CaMKIIalpha 49471 1Generation of a severe memory deficit mutant mouse by exclusively eliminating the kinase activity of CaMKIIalpha 49471 2NOAA forecast predicts large dead zone for Gulf of Mexico this summer 8922 1NOAA forecast predicts large dead zone for Gulf of Mexico this summer 8922 2NOAA forecast predicts large dead zone for Gulf of Mexico this summer 8922 3
...LONDON, June 11 Morria Biopharmaceuticals Plc, a,...nt of novel,anti-inflammatory drugs, today announc...he South African Medicines Control Council (MCC) t...ts suffering from allergic rhinitis,(AR). The two-...-controlled,study includes a steroid comparator ar...
...Lead Candidate Set for Phase II Clinicals, LA JOL...Bulletin Board: DSKA) ("Duska" or the "Company"), ...ive, worldwide license from Duke,University and Jo...e their,rights to a portfolio of investigational c...lure. The most advanced drug in the portfolio is,e...
Other Medicine Technology:Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis 2Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins 2Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins 3
(Date:11/25/2009)...ewswire/-SentinelleMedicalInc.,aleadingmanufacture...dCalgaryScientificInc.,aleadingproviderofsoftwaree...is(TM)Breast4DAdvancedVisualizationsoftware. ,,...intWebclientbasedmedicalimagingofferinginthemarket...ro-footprintaccess-requiringnosoftwaredownload,and...
(Date:11/25/2009)...-USNewswire/--TheBlackAIDSInstituterecentlyheldBoa...pfor2010. ,, ThenewBoardMembersareahighlydivers...inance,governmenthealthprograms,editorial,andbusin...eofpersonalbackgroundsincludingbothheterosexualand...drepresentingmultipleagegroups. ,, (Photo: http...
(Date:11/25/2009)... a statistically significant survival benefit from...receptor (ER)-positive tumors had high levels of p...a S118-P), according to a brief communication publ...tional Cancer Institute . , Approximately 50% of...clinical studies have shown that ER-alpha S118-P i...
(Date:11/25/2009)...umatoid arthritis, could help newly diagnosed diab...5 (HealthDay News) -- A drug commonly used to trea...now also shows some promise in helping patients ne... rituximab (Rituxan), helped patients keep produci...ase had destroyed some of their pancreatic beta ce...
(Date:11/25/2009)...signs of trouble with the H1N1 vaccine, , ...going H1N1 swine flu pandemic may be driving a rec...tients, a U.S. health official said Wednesday. ,...al infections around the country," Dr. Anne Schuch...on and Respiratory Diseases at the U.S. Centers fo...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 2Health News:Swine Flu Tied to Rise in Pneumonias Among Young 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 4
...11th annual awards recognize technology innovation.... 22 The,Microsoft Healthcare Users Group (MS-HUG...ntries for the 2008 MS-HUG Healthcare Innovation,A...are. (Logo: http://www.newscom.com/cgi-bin/prnh/...
...ATLANTA, Oct. 22 Vendormate VISION, the healthcar... and ethics compliance,monitoring, makes it easier...hey care about most with the release of VISION 4.0...es to distance themselves from the competition by,...
..., Scientists from developing countries are vitall... be given the proper resources to conduct their wo...in the journal Nature Immunology. , Researchers...cies must commit to sharing technology and experti...
..., Scientists still do not know what causes epilep...rd Florey Institute are one step closer to solving...d genetically modified epileptic mouse. , This is...ou and his team to understand the genesis of epile...
...Review of 100,000 California seniors finds too few...- The quality of care received by vulnerable elder...e, a team of U.S. researchers report. , Researcher... at 43 specific types of care received by more tha...
...Solid Performance Continues in Third Quarter of 20...tion of Organon BioSciences, KENILWORTH, N.J., Oc...oday reported financial results for the third,quar...animal health business. "Schering-Plough has now ...
Other Medicine News:Health News:Call for Entries Announced for 2008 MS-HUG Innovation Awards 2Health News:Call for Entries Announced for 2008 MS-HUG Innovation Awards 3Health News:Vendormate VISION 4.0(TM) Streamlines Healthcare Security and Compliance Efforts 2Health News:Fight against HIV needs local scientists, say researchers 2Health News:Childhood epilepsy research offers new hope for seizure control 2Health News:Most Elderly Don't Get Good Medical Care: Study 2Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 2Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 3Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 4Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 5Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 6Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 7Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 8Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 9Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 10Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 11Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 12Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 13Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 14Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 15Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 16Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 17Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 18
Knot Pusher
... Arthroscopy Scissor is ideal for excising soft ti...debris in the joint. The serrated edge on the stra...s hold tissue within the jaws for more efficient r...and right jaw curvatures, are the perfect tools fo...
... Arthroscopy Scissor is ideal for excising soft ti...debris in the joint. The serrated edge on the stra...s hold tissue within the jaws for more efficient r...and right jaw curvatures, are the perfect tools fo...
... Series I Instrument program offers state-of-the-a...le, while maintaining strength and durability. Low... tight joint spaces. Series I instruments are avai...and angle required for large and small joint arthr...
Medicine Products: